Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Taranabant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 known ✓ | P21554 | 20/20 | 1.00 |
| ▸ | CNR2 | P34972 | 9/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taranabant SCHEMBL17565778 | 1.00 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| Taranabant SCHEMBL13253304 | 1.00 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| Taranabant SCHEMBL501972 | 1.00 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| Taranabant SCHEMBL4024243 | 1.00 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| Taranabant SCHEMBL29434856 | 1.00 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| Taranabant SCHEMBL13253294 | 1.00 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL3474367 | 0.95 | CNR1 (0.90) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL3474366 | 0.95 | CNR1 (0.90) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL3475455 | 0.93 | CNR1 (0.87) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL16357820 | 0.93 | CNR1 (0.87) | CNR1CNR2CYP2D6CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 702 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| US-20250352559-A1 | Transdermal Delivery Composition for Delivery of at least one Glucose Controlling Agent, and Method of Delivering at least one Glucose Controlling Agent | SKINVISIBLE PHARMACEUTICALS INC (US) | 2025-11-20 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4486336-A2 | CB1 LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | Adarx Pharmaceuticals, Inc. (US) | 2025-01-08 | — | — | EP | claimed |
| US-20240408059-A1 | METHOD OF TREATING ADDICTION | ANEBULO PHARMACEUTICALS, INC. | 2024-12-12 | — | — | US | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| US-20230330111-A1 | ACTIVE AGENT COMBINATION FOR TREATMENT OF CANCER | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2023-10-19 | — | — | US | claimed |
| WO-2023168296-A2 | CB1 LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-09-07 | — | — | WO | claimed |
| EP-4203944-A1 | ACTIVE AGENT COMBINATION FOR TREATMENT OF CANCER | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH (DE) | 2023-07-05 | — | — | EP | claimed |
| WO-2022198259-A1 | TREATMENT METHODS FOR PULMONARY ARTERIAL HYPERTENSION | THE HEART RESEARCH INSTITUTE LTD (AU) | 2022-09-29 | — | — | WO | claimed |
| WO-2022043490-A1 | ACTIVE AGENT COMBINATION FOR TREATMENT OF CANCER | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2022-03-03 | — | — | WO | claimed |
| EP-2739262-B1 | USE OF A CB1 RECEPTOR ANTAGONIST AS A WHITENING AND/OR ANTI-BROWNING AGENT FOR KERATIN MATERIAL | OREAL (FR) | 2017-09-27 | — | — | EP | claimed |
| US-9662320-B2 | Antagonists of the cannabinoid receptor CB1 for use in the treatment of diseases associated with neuronal dendritic abnormalities | UNIVERSITAT POMPEU FABRA (ES) | 2017-05-30 | — | — | US | claimed |
| US-20160067235-A1 | Antagonists of the Cannabinoid Receptor CB1 for Use in the Treatment of Diseases Associated with Neuronal Dendritic Abnormalities | UNIVERSITAT POMPEU FABRA (ES) | 2016-03-10 | — | — | US | claimed |
| EP-2739262-A2 | USE OF A CB1 RECEPTOR ANTAGONIST AS A WHITENING AND/OR ANTI-BROWNING AGENT FOR KERATIN MATERIAL | L'OREAL (FR) | 2014-06-11 | — | — | EP | claimed |
| US-8715648-B2 | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics | PIVOTAL THERAPEUTICS INC. (CA) | 2014-05-06 | — | — | US | claimed |
| WO-2013021129-A2 | USE OF A CB1 RECEPTOR ANTAGONIST AS A WHITENING AND/OR ANTI-BROWNING AGENT FOR KERATIN MATERIAL | L'OREAL (FR) | 2013-02-14 | — | — | WO | claimed |
| US-20090306037-A1 | Combination of a Dipeptidyl Peptidase-IV Inhibitor and a Cannabinoid CB1 Receptor Antagonist for the Treatment of Diabetes and Obesity | MERCK & CO., INC. (US) | 2009-12-10 | — | — | US | claimed |
| US-20060270650-A1 | Combination therapy for the treatment of obesity | MACNEIL TANYA | 2006-11-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408059-A1 | METHOD OF TREATING ADDICTION | CNR2, CNR1, OPRM1 | CNR1 2/4885CNR2 1/4885CYP2D6 533/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | CNR1 221/4885CNR2 204/4885CYP2D6 1028/4885 |
| US-20230330111-A1 | ACTIVE AGENT COMBINATION FOR TREATMENT OF CANCER | GLS2, AGK, GLS | CNR1 3466/4885CNR2 3282/4885CYP2D6 2211/4885 |
| US-20250352559-A1 | Transdermal Delivery Composition for Delivery of at least one Glucose Controlling Agent, and Method of Delivering at least one Glucose Controlling Agent | SLC2A1, SLC2A4, SLC2A8 | CNR1 2558/4885CNR2 3030/4885CYP2D6 1106/4885 |
| US-20090306037-A1 | Combination of a Dipeptidyl Peptidase-IV Inhibitor and a Cannabinoid CB1 Receptor Antagonist for the Treatment of Diabetes and Obesity | DPP4, DPP3, DPP7 | CNR1 6/4885CNR2 10/4885CYP2D6 831/4885 |
| US-20160067235-A1 | Antagonists of the Cannabinoid Receptor CB1 for Use in the Treatment of Diseases Associated with Neuronal Dendritic Abnormalities | CNR1, CNR2, DBN1 | CNR1 1/4885CNR2 2/4885CYP2D6 4659/4885 |
| US-20060270650-A1 | Combination therapy for the treatment of obesity | GPR119, GANC, GANAB | CNR1 385/4885CNR2 281/4885CYP2D6 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.